KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Equity Average (2016 - 2025)

Historic Equity Average for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $91.1 billion.

  • Pfizer's Equity Average rose 87.24% to $91.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $91.1 billion, marking a year-over-year increase of 87.24%. This contributed to the annual value of $90.5 billion for FY2024, which is 6421.33% up from last year.
  • Latest data reveals that Pfizer reported Equity Average of $91.1 billion as of Q3 2025, which was up 87.24% from $89.8 billion recorded in Q2 2025.
  • Pfizer's 5-year Equity Average high stood at $100.3 billion for Q3 2023, and its period low was $53.1 billion during Q4 2022.
  • Its 5-year average for Equity Average is $81.3 billion, with a median of $89.8 billion in 2025.
  • In the last 5 years, Pfizer's Equity Average surged by 8511.08% in 2023 and then crashed by 997.16% in 2024.
  • Pfizer's Equity Average (Quarter) stood at $56.7 billion in 2021, then rose by 1.02% to $57.3 billion in 2022, then surged by 62.74% to $93.2 billion in 2023, then fell by 2.92% to $90.5 billion in 2024, then rose by 0.58% to $91.1 billion in 2025.
  • Its Equity Average stands at $91.1 billion for Q3 2025, versus $89.8 billion for Q2 2025 and $89.6 billion for Q1 2025.